Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 35%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is viewed positively because a broadening recovery in bioprocessing, life sciences, and diagnostics is underpinning outsized sales growth, with bioprocessing representing more than 25% of revenue and showing strong consumables demand plus >30% growth in equipment orders. Q2 showed resilient execution: revenue was $6.27B, core revenue rose 3.0%, adjusted operating margin was 27.1%, adjusted EPS was $1.94, and free cash flow reached $1.3B in the quarter, while management raised full-year 2026 EPS guidance to $8.45–$8.60. The company’s best-in-class portfolio, high share in chromatography resins, improving end markets, and durable long-term demand from pharma reshoring and expanding molecular diagnostics support confidence that growth can re-accelerate as temporary timing issues normalize.

Bears say

Danaher is viewed negatively because its growth rebound has stalled across key end markets, with bioprocess equipment demand still awaiting a reshoring-driven pickup, Life Sciences instrument demand continuing to decline, and China diagnostics remaining a drag even as sales there are now below $1B annually. The company’s late 2023 divestiture of Veralto left it more concentrated in life sciences and diagnostics, making execution on product demand and acquisition integration more critical just as several recent Life Sciences deals have failed to meet expectations. With the stock now vulnerable to a 15x P/E, investors appear less willing to award the company a premium, especially if frustration persists over sluggish organic growth and limited evidence that press releases will translate into purchase orders.

Danaher (DHR) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 35% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 17 analysts, Danaher (DHR) has a Buy consensus rating as of Oct 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $235.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $235.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.